Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A protein interaction landscape of breast cancer.
Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M, Soucheray M, McGregor MJ, O'Leary P, Wolf D, Stevenson E, Foo TK, Mitchell D, Herrington KA, Muñoz DP, Tutuncuoglu B, Chen KH, Zheng F, Kreisberg JF, Diolaiti ME, Gordan JD, Coppé JP, Swaney DL, Xia B, van 't Veer L, Ashworth A, Ideker T, Krogan NJ. Kim M, et al. Among authors: munoz dp. Science. 2021 Oct;374(6563):eabf3066. doi: 10.1126/science.abf3066. Epub 2021 Oct 1. Science. 2021. PMID: 34591612 Free PMC article.
Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?
Capogiri M, De Micheli AJ, Lassaletta A, Muñoz DP, Coppé JP, Mueller S, Guerreiro Stucklin AS. Capogiri M, et al. Among authors: munoz dp. Front Oncol. 2023 Jan 9;12:1074726. doi: 10.3389/fonc.2022.1074726. eCollection 2022. Front Oncol. 2023. PMID: 36698391 Free PMC article. Review.
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. Ruiz-Saenz A, et al. Among authors: munoz dp. Nat Cancer. 2023 Feb;4(2):240-256. doi: 10.1038/s43018-022-00508-5. Epub 2023 Feb 9. Nat Cancer. 2023. PMID: 36759733 Free PMC article.
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Chong SJF, et al. Among authors: munoz dp. J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169. J Clin Invest. 2023. PMID: 37751299 Free PMC article.
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. Feichtenschlager V, et al. Among authors: munoz dp. Mol Cancer. 2024 Feb 22;23(1):40. doi: 10.1186/s12943-024-01955-7. Mol Cancer. 2024. PMID: 38383439 Free PMC article.
249 results